AstraZeneca has received FDA approval for vandetanib as an orphan drug treatment for medullary thyroid cancer that cannot be removed by surgery or has spread to other parts of the body. While AstraZeneca has not disclosed a launch date, “we will work to make [vandetanib] available to patients as soon as possible and will make another announcement at that time,” AstraZeneca spokeswoman Laura Woodin told DID.
Apparently, the FDA nixed the trade name Zictifa, the second name AstraZeneca has attached to the drug. It is “working with the FDA on a new trade name,” Woodin said.
Drug Industry Daily